DMK-Congress seat sharing pact: Congress to contest 25 seats in Tamil Nadu

News Network
March 7, 2021

Chennai, Mar 7: Congress on Sunday announced its seat-sharing agreement with Dravida Munnetra Kazhagam (DMK) and will contest in 25 assembly seats in the upcoming Tamil Nadu election and in the by-election to the Kanyakumari Lok Sabha seat, according to state Congress Chief KS Alagiri.

Elections to the 234-seat Tamil Nadu Assembly will be held in a single phase on April 6. The results will be announced on May 2. Besides the Congress, the alliance includes two Communist parties, the Marumalarchi Dravida Munnetra Kazhagam, the Viduthalai Chiruthaigal Katchi, the Indian Union Muslim League and the Manithaneya Makkal Katchi.

While the DMK has signed a deal for six seats with the Communist Party of India, it is yet to finalise a seat-sharing agreement with the Communist Party of India (Marxist) and the Marumalarchi Dravida Munnetra Kazhagam.

On Friday, the ruling All India Anna Dravida Munnetra Kazhagam had inked a seat-sharing agreement with the Bharatiya Janata Party, allotting its ally 20 Assembly seats for the upcoming polls.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com news network
April 13,2021

Bengaluru, Apr 13: Amidst continued threats of covid-19, the government of Karnataka has issued special guidelines for Muslims during the month of Ramdan. As per the guidelines, masjids in containment zones to remain closed till the zone is denotified, large gathering continues to remain prohibited, face masks mandatory.

Here is the complete guidelines:

guidlines.jpg

guidlines2.jpg

guidlines3.jpg

guidlines4.jpg

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 8,2021

Mysuru, Apr 8: As Covid-19 cases surge in Karnataka, especially in Bengaluru urban, people coming to Mysuru from the state capital have been advised to get Covid negative report.

Deputy Commissioner Rohini Sindhuri has suggested people travelling to Mysuru carry a test report. The DC said a large number of people travel between the two cities for business and other purposes.

The DC also made it mandatory for tourists to carry a negative report.

"In this regard, it is appropriate for those travelling to Mysuru district from Bengaluru to have a Covid-19 negative report (not older than 72 hours). It is hereby requested to cooperate to control the Covid-19 spread by following the advisory," it added.

Speaking to reporters, the Deputy Commissioner said that those going to tourist spots, convention and party halls, recreational clubs and cinema halls will have to carry Covid- 19 negative reports, from April 10 to 20 in the wake of Ugadi festivities and related holidays.

"Though we are not closing down any of the tourist places, as many tourists are coming in, wherever people gather, a negative report is to be carried," she said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 13,2021

New Delhi, Apr 13: The Russian Direct Investment Fund (RDIF) has said that India has become the 60th country to approve the use of Sputnik V against coronavirus and more than 850 million doses of the vaccine are going to be produced in the country annually.

The Drug Controller General of India (DCGI) has registered the vaccine under the emergency use authorisation procedure. This is based on results of clinical trials in Russia as well as positive data of additional Phase III local clinical trials in India conducted in partnership with Dr Reddy’s Laboratories.

The vaccine has been approved for use in countries with a total population of 3 billion people or about 40 per cent of the global population, and India has become the 60th country to approve Sputnik V, RDIF, Russia's sovereign wealth fund, said in a statement.

Also Read | DCGI gives nod to Russian Covid-19 vaccine Sputnik V

India is also the most populated country to register the vaccine and also the leading production hub for Sputnik V, it added.

RDIF CEO Kirill Dmitriev said the approval of the vaccine is a major milestone as both countries have been developing an extensive cooperation on clinical trials of Sputnik V in India and its local production.

"The Russian vaccine has efficacy of 91.6 per cent and provides full protection against severe cases of Covid-19 as demonstrated by the data published in one of the leading medical journals -- The Lancet," he added.

Noting that India is a vaccine-manufacturing hub and a strategic partner for production of Sputnik V, he said RDIF has created partnerships with a number of India's leading pharmaceutical companies for production of Sputnik V which will provide for both vaccination of the population in India and global distribution of the vaccine.

"Over 850 million doses of Sputnik V are going to be produced in India annually sufficient to vaccinate more than 425 million people around the world," he said.

According to the release, RDIF has agreements with India's Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech aimed at production of more than 850 million doses per year.

Also Read | All you need to know about the Sputnik V Covid-19 vaccine

Sputnik will be the third vaccine to be used in India against coronavirus. In January, DCGI had given the emergency use authorisation for two Covid-19 vaccines -- Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca manufactured by Serum Institute of India in Pune.

As per RDIF, Sputnik V has a number of key advantages, including that there are no strong allergies caused by Sputnik V.

The price of the vaccine is less than $10 per shot and it uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots, it added.

Other countries that have approved use of Sputnik V include Argentina, Bolivia, Hungary, UAE, Iran, Mexico, Pakistan, Bahrain and Sri Lanka.
 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.